|
|
5-day change | 1st Jan Change | ||
|
103.78 USD |
-0.17% | +2.36% | +15.79% | |
Published on 04/30/2025 at 11:05
© MT Newswires – 2025
|
Lantheus Says Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Primary Endpoints in Two Trials |
11:05am |
MT |
|
Lantheus Announces Alzheimer’s Disease Radiodiagnostic Mk-6240 Meets Co-Primary Endpoints In Two Pivotal Studies |
08:36am |
RE |
|
Lantheus Closes Evergreen Theragnostics Acquisition |
Apr. 01 |
MT |
|
B. Riley Cuts Price Target on Lantheus Holdings to $122 From $127, Keeps Buy Rating |
Mar. 21 |
MT |
|
Lantheus Holdings Insider Sold Shares Worth $5,010,734, According to a Recent SEC Filing |
Mar. 05 |
MT |
|
Truist Adjusts Price Target on Lantheus Holdings to $127 From $120, Maintains Buy Rating |
Feb. 27 |
MT |
|
Sector Update: Health Care Stocks Slip in Afternoon Trading |
Feb. 26 |
MT |
|
Lantheus Shares Gain as Q4 Results Beat Forecasts, Upbeat Outlook Issued |
Feb. 26 |
MT |
|
Stocks in motion: Intuit and Axon rise on great results, Applovin tumbles on short-seller attack |
Feb. 26 |
 |
|
Lantheus Holdings, Inc., Q4 2024 Earnings Call, Feb 26, 2025 |
Feb. 26 |
|
|
Tranche Update on Lantheus Holdings, Inc.’s Equity Buyback Plan announced on November 20, 2024. |
Feb. 26 |
CI |
|
Lantheus Q4 Adjusted Earnings Decline, Revenue Increases; 2025 Outlook Issued |
Feb. 26 |
MT |
|
Earnings Flash (LNTH) Lantheus Holdings Reports Q4 Revenue $391.1M, vs. FactSet Est of $376.1M |
Feb. 26 |
MT |
|
(LNTH) Lantheus Holdings Expects Fiscal Year 2025 Adjusted EPS Range $7.00 – $7.20 |
Feb. 26 |
MT |
|
Earnings Flash (LNTH) Lantheus Holdings Posts Q4 Adjusted EPS $1.59, vs. FactSet Est of $1.54 |
Feb. 26 |
MT |
|
Lantheus Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Feb. 26 |
CI |
|
Lantheus Holdings, Inc. Provides Earnings Guidance for the Year 2025 |
Feb. 26 |
CI |
|
B. Riley Adjusts Lantheus Holdings Price Target to $127 From $146, Maintains Buy Rating |
Feb. 12 |
MT |
|
Lantheus Holdings, Inc. Appoints Phuong Khanh (P.K.) Morrow, M.D., to the Board of Directors, Effective February 1, 2025 |
Jan. 30 |
CI |
|
Evergreen Theragnostics, Inc., Lantheus Holdings, Inc. – M&A Call |
Jan. 28 |
|
|
Lantheus Holdings to Acquire Evergreen Theragnostics in All-Cash Transaction |
Jan. 28 |
MT |
|
Lantheus Holdings, Inc., Life Molecular Imaging GmbH – M&A Call |
Jan. 13 |
|
|
Lantheus Holdings to Acquire Life Molecular Imaging for Up to $750 Million |
Jan. 13 |
MT |
|
Radiopharm Theranostics Raises $5 Million in Private Placement With Lantheus |
Jan. 10 |
MT |
|
Radiopharm Theranostics Limited announced that it has received AUD 7.98 million in funding from Lantheus Holdings, Inc. |
Jan. 08 |
CI |
LNTH: Dynamic Chart
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol. It has pre-clinical assets, specifically the TROP2 and DUNP19.
More about the company
Buy
Last Close Price
103.96USD
Average target price
134.38USD
Spread / Average Target
+29.27%
Consensus
Select your edition
All financial news and data tailored to specific country editions
